Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca’s Zavicefta meets main goals in phase III trial to treat hospital-acquired pneumonia AstraZeneca has unveiled positive results from a phase III trial of its Zavicefta antibiotic, a fixed dose combination of two active substances, ceftazidime and avibactam. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

TauRx's LMTX Alzheimer's drug fails to meet co-primary endpoints in phase 3 trial
By PBR Staff Writer
TauRx Therapeutics’ experimental Alzheimer's drug LMTX has failed to meet its co-primary endpoints in a phase 3 clinical trial.
Contract Research & Services > Clinical Trials > News
Neurovance’s centanafadine ADHD drug meets main goals in phase 2b trial
By PBR Staff Writer
The phase 2b trial of Neurovance’s centanafadine SR (CTN), a non-stimulant for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD), has met both the primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News

Contract Research

Codexis completes obligations under research and development deal with biopharmaceutical firm
Codexis has completed its obligations under a collaborative research and development agreement with a leading global biopharmaceutical company.
Contract Research & Services > Contract Research > News
Pfizer, Western Oncolytics establish immuno-oncology research collaboration
Pfizer and Western Oncolytics have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12.
Contract Research & Services > Contract Research > News

Contract Services

Profil Institute, HighTide Biopharmaceutical partner to develop new therapies for diabetes and NAFLD/NASH
Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, announced today a strategic master services agreement with Shenzhen HighTide Biopharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical.
Contract Research & Services > Contract Services > News
Almirall, Sun Pharma sign license deal to develop tildrakizumab for psoriasis in Europe
Sun Pharma, Sun Pharmaceutical Industries and its subsidiaries or associate companies, and Almirall have signed a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe.
Contract Research & Services > Contract Services > News